Please login to the form below

Not currently logged in
Email:
Password:

ponatinib

This page shows the latest ponatinib news and features for those working in and with pharma, biotech and healthcare.

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda's gamble on Ariad pays off with Alunbrig approval

Takeda agreed to buy Ariad earlier this year in a $5.2bn deal, which included already-marketed haematological cancer drug Iclusig (ponatinib) as well as a pipeline of oncology candidates headed

Latest news

More from news
Approximately 12 fully matching, plus 10 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    treatment Iclusig (ponatinib) - both in the US and Europe. “ ... And that was absolutely correct.”. After selling off investigational sarcoma treatment ridaforolimus to Merck &Co following an aborted collaboration attempt, ponatinib emerged as the

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ariad appoints new board member Ariad appoints new board member

    Ariad will look to benefit Denner's experience as it prepares to grow the market share of leukaemia drug Iclusig (ponatinib).

  • Jonathan Dickinson joins Ariad from BMS Jonathan Dickinson joins Ariad from BMS

    He joins at an important time for Ariad in Europe as it prepares to launch its chronic myeloid leukaemia treatment Iclusig (ponatinib), pending approval from the European Commission (EC).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics